ncbi.nlm.nih.gov/pmc/articles/P…

As if this graph was not bad enough, new data to layer on: administrative costs. In 2017, for US it was 34.2% of all health expenditures; for Canada it was 17.0%. Per capita 4.5X annals.org/aim/fullarticl… Annals of Int Med by Steffie Woolhandler Terry Campbell Graph: economist.com/graphic-detail…

Individual and community-level risk for COVID-19 mortality in the United States | Nature Medicine nature.com/articles/s4159…

My one-pager on the mRNA vaccines cell.com/cell/fulltext/… Cell

Another variation of this theme is assessing AS in A Fib with different cycle lengths. #Nkomo Mayo Clinic CV have the data that a single highest LVOT and AV velocities can reflect the severity of AS , better than averaging 3 or 5 cycles which is time consuming. See figure below.

Understanding Academic Medical Centers: Simone’s Maxims | Clinical Cancer Research clincancerres.aacrjournals.org/content/5/9/22…

In patients hospitalised with #COVID19 & elevated D-dimer, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by riva to day 30 did not improve clinical outcomes & increased bleeding compared with prophylactic anticoagulation thelancet.com/journals/lance…

Good news for coffee drinkers ☕️☕️ Debunking the dogma that coffee increases the risk of heart rhythm disturbances, from >386,000 people, 4.5 year follow-up, including putative genomic risk variants JAMA Internal Medicine jamanetwork.com/journals/jamai… UK Biobank

What’s actually happening in thoracic outlet syndrome ⬇️ Via Paul #MedTwitter

🎓Congrats to our graduating fellows! Thank you for your endless support, teaching, and friendship - not to mention your time at the COVID epicenter during the height of the pandemic. The future of cardiology is bright 😎 Imad Bagh @M_CagliostroMD Eman R. Rashed, MD, PhD dsternheim

Coffee lovers will love this new report ;-) academic.oup.com/eurjpc/advance… European Society of Cardiology Baker Institute UK Biobank ☕️☕️☕️

How to ace your cardiology interview

Give a talk on tips for getting a paper published for early career docs. I had fun putting it together with my own reflections as a jr. author, sr. author, peer reviewer, and editor. I thought I would share a 🧵 @svm_tweets #ACCFIT #SVMNextGen #publishing

Horrendous hemorrhagic complications with OAC in ESRD with AFib : “The 1-year rates for major or clinically relevant non-major bleeding were 32% and 26% in apixaban and warfarin groups, respectively”. Worse mortality for apixaban as well (26% vs 18%) ahajournals.org/doi/10.1161/CI….

This prematurely terminated CANARY Trial of patients with intermediate-high–risk PE was hypothesis-generating for improvement in some efficacy outcomes and acceptable rate of major bleeding for catheter-directed lysis compared with anticoagulation Here: jamanetwork.com/journals/jamac…

More highlights from this weekend - reuniting with friends and mentors 📸 #ACC23 #ACCFIT American College of Cardiology Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai NYC Health + Hospitals

Repost if you agree (and plz comment): The time is NOW for vascular medicine ⁦Society for Vascular Medicine | SVM⁩ ⁦Josh Beckman⁩ ⁦Raghu Kolluri⁩ ⁦herbaronowMD⁩ ⁦Geno Merli MD⁩ ⁦Ido Weinberg, MD⁩ Bruce Gray journals.sagepub.com/doi/10.1177/13…

Disappointing news. Fact is we will not see this drug for several years. But since these were extremely high risk folks, it seems like there should at least be a signal or trend of MACE reduction with pelacarsen drastically lowering Lp(a) that would at least make continuing the